At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 128 enrolled
Drug / intervention
TRC105 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 3 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma (TAPPAS)
In Brief
A Phase 3 clinical trial evaluating TRC105 and Votrient for Advanced Angiosarcoma. Completed, enrolled 128 participants across 39 sites in 8 countries.
Detailed Summary
This is a study of TRC105 in combination with standard dose pazopanib compared to single agent pazopanib in patients with angiosarcoma not amenable to curative intent surgery (e.g., metastatic or bulky disease, and disease for which surgical resection would carry an unacceptable risk to the patient) who have not received pazopanib or TRC105 previously.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Angiosarcoma
CountriesAustria, France, Germany, Italy, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartFeb 2017
Primary CompletionApr 2019
Study CompletionAug 2019
TodayJul 2026
First PostedDec 2, 2016
Enrollment StartFeb 13, 2017
Primary CompletionApr 11, 2019
Study CompletionAug 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 9.6 years ago
Interventions
TRC105biological
TRC105 antibody
Votrientdrug
pazopanib